Clinical Sciences Core Research Plan (C)

临床科学核心将由Margaret FischI博士担任主任，Charles Mitchell博士担任联合主任，Kristopher Arheart博士担任生物统计子核心负责人。临床科学核心（CSC）在过去的四年中提供了必要的服务，既提高了迈阿密CFAR研究者和新/年轻研究者的生产力和能力，又促进了临床，行为/社会和基础科学家之间的合作研究，涉及人类受试者，人类数据和生物标本的收集和分配。CSC为7 NIH研究所、6 NIH资助的网络、CDC、HRSA和制药行业支持的120多个项目的80多名研究人员提供了支持和服务，并为包括年轻/新研究人员在内的100多名CFAR成员提供了支持。 CSC的使命是提供科学领导和基础设施支持，推动基础、临床、流行病学、行为/社会和转化科学领域的多学科合作研究，以预防、检测、治疗和治愈艾滋病毒/艾滋病。CSC的使命和目标是需求基础，由UM CFAR调查人员及其项目的研究优先事项和CSC优先事项驱动，以促进协同作用并产生规模经济。CSC将侧重于提高NIH网络的艾滋病毒/艾滋病研究能力，促进和支持创新的NIH艾滋病毒/艾滋病研究倡议，并促进和促进CFAR研究人员与行业之间的科学互动。CSC将通过提供生物统计学研究设计专业知识和生物统计学服务、提供临床数据和生物标本储存库以促进协作免疫发病机制研究、协助IRB和监管机构提交文件以及提供最先进的临床研究设施和临床服务来实现这一目标。 CSC对迈阿密CFAR的持续增长和成功至关重要，因为它为推进迈阿密大学其他核心或设施无法复制的治疗，疫苗和预防研究的多学科临床翻译研究提供了关键的专业知识和服务。

The Clinical Sciences Core will be led by Dr. Margaret FischI as Director, Dr. Charles Mitchell as Co- Director, and Dr. Kristopher Arheart as Biostatistical Subcore leader. The Clinical Sciences Core (CSC) during the past four years provided essential services that both enhanced the productivity and capacity of Miami CFAR investigators and new/young investigators and fostered collaborative research among clinical, behavioral/social, and basic scientists that involved human subjects, human data, and biological specimen collection and distribution. The CSC provided support and services to over 80 investigators for over 120 projects support by 7 NIH institutes, 6 NIH funded networks, the CDC, the HRSA, and the pharmaceutical industry and to over 100 CFAR members including young/new investigators. The mission of the CSC is to provide scientific leadership and infrastructure support that advances multidisciplinary collaborative research in basic, clinical, epidemiologic, behavioral/social, and translational sciences in the prevention, detection, treatment, and cure of HIV/AIDS. The mission and goals of the CSC are needs base driven by the research priorities of the UM CFAR investigators and their projects and by the CSC priority to foster synergy and produce an economy of scale. The CSC will focus on enhancing the capacity for HIV/AIDS research in NIH Networks, promoting and supporting innovative NIH HIV/AIDS research initiatives, and facilitating and promoting scientific interactions between CFAR investigators and industry. The CSC will accomplish this through the provision of Biostatistical study design expertise and biostatical services, provision of clinical data and biological specimen repository to foster collaborative immunopathogenesis research, assistance with IRB and regulatory agency submissions, and provision of state-of-the-art clinical research facilities with clinical services. The CSC is essential to the continued growth and success of the Miami CFAR, as it has provided critical expertise and services for advancing multidisciplinary clinical translation research in therapeutic, vaccine and prevention research that is not duplicated by other Cores or facilities at the University of Miami.